Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM

Diabetes Care

Volumn 21, Issue 5, 1998, Pages 817-821

  Attia, Najya ^a   Jones, Timothy W ^a   Holcombe, John ^b   Tamborlane, William V ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN LISPRO; NEUTRAL INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DIABETIC KETOACIDOSIS; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; MALE;

EID: 0031735540     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.5.817     Document Type: Article

References (12)

1. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR: (Lys(B28), Pro(B29)) human insulin: a rapidly absorbed analogue of human insulin. Diabetes 43:396-402, 1994
2. DiMarchi RD, Chance RE, Long HB, Shields JE, Slicker LJ: Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor 1. Horm Res 41 (Suppl. 2):92-96, 1994
3. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, DiVincenzo A, Epifano L, Ciofetta M, Pampanelli S, Brunetti P, Bolli GB: Pharmacokinetics, pharmacodynamics, and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue (Lys(B28), Pro(B29)) in IDDM. Diobetologia 37:713-720, 1995
4. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T: Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 46:440-443, 1997
5. Pen P, Hinselmann C, Pfutzner A, Dreyer M: Catheter disconnection in type 1 diabetes treated with CSII: comparison of insulin lispro and human regular insulin (Abstract). Diabetologia 39 (Suppl. 1):A847, 1996
6. Castillo MJ, Scheen AJ, Lefebvre PJ: The degree/rapidity of the metabolic decompensation following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose level. J Clin Endocrinol Metab 81:1975-1978, 1996
7. Williamson DH, Mellanby J, Krebs HA: Enzymatic determination of D(-)-βhydroxybutyric acid and acetoacetic acid in blood. Biochem J 82:90-96, 1962
8. Anderson JH, Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, DiMarchi R, the Multicenter Insulin Lispro Study Group: Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin analog treatment. Diabetes 46:265-270, 1997
9. Garg SK, Carmain JA, Braddy KG, Anderson JH, Vignati L, Jennings MK, Chase HP: Premeal insulin analogue insulin lispro vs. humulin R insulin treatment in young subjects with type 1 diabetes. Diabet Med 13:47-52, 1996
10. Pfutzner A, Kustner E, Forst T, Schulze-Schleppinghoff B, Trautman ME, Haslbeck M, Schatz H, Beyer J: Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 104:25-30, 1996
11. Lougheed WD, Zinman B, Strack TR, Janis LJ, Weymouth AB, Bernstein EA, Korbas AM, Frank BH: Stability of insulin lispro in insulin infusion systems. Diabetes Care 20:1061-1065, 1997
12. B29-human insulin analog and regular human insulin in the correction of incidental hyperglycemia. Diabetes Care 19:1426-1429, 1996